EGFR and lung adenocarcinoma: The Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) remain the mainstay of targeted therapy for Non-Small Cell Lung Cancer (NSCLC) because EGFR mutations occur in 50% of patients with lung adenocarcinomas in the Asian population (1–3).